Revolution Medicines (RVMD) announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. Sandler joins Revolution Medicines from ALX Oncology, where he most recently served as CMO. As a further step in building global commercial capabilities, Revolution Medicines has also appointed two key regional leaders: Alicia Gardner as senior vice president, general manager for the U.S. region, and Gerwin Winter as senior vice president, general manager for the European region. Alicia and Gerwin will play important leadership roles as the company prepares for the potential approvals and commercial launches of daraxonrasib in patients with cancers driven by RAS, including pancreatic ductal adenocarcinoma, as well as other innovative targeted medicines for patients living with RAS-addicted cancers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Strategic Positioning and Promising Phase 3 Trials Drive Buy Rating
- Revolution Medicines price target raised to $71 from $70 at JPMorgan
- These 2 Stocks Could Be Prime Takeover Targets, According to Analysts
- Revolution Medicines resumed with a Strong Buy at Raymond James
- Revolution Medicines rises 14.2%